News / News Bulletin

Immunotherapy for Alzheimer’s disease shows promise

Thursday, 01 September 2016 7:50 AM [ Last Update: Thursday, 01 September 2016 8:23 AM ]

In a trial of 165 people, brain scans showed reductions in amyloid-beta plaques (red) in people given the antibody aducanumab compared with a placebo. Higher doses caused more amyloid reduction.

Scientists have tested a new drug with promising results in controlling Alzheimer’s disease.

American and Swiss researchers conducted the experiment on 165 people with early-stage Alzheimer.

The group was given a monthly injection of the antibody and was compared with those on placebo drugs.

The trial drug known as "aducanumab" cleared abnormal protein clogs in the patients and slowed their mental decline.

The experts, however, have warned against overestimating the results, saying it is too soon to consider the drug as a definitive treatment for the illness which robs people’s memory and independence.

Press TV’s website can also be accessed at the following alternate addresses:

www.presstv.co.uk

The Lite